These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19059062)

  • 21. Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene.
    Novillo A; Romero-Lorca A; Gaibar M; Rubio M; Fernández-Santander A
    Pharmacogenomics J; 2017 Mar; 17(2):109-111. PubMed ID: 27698402
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
    Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
    Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
    Brauch H; Schroth W; Goetz MP; Mürdter TE; Winter S; Ingle JN; Schwab M; Eichelbaum M
    J Clin Oncol; 2013 Jan; 31(2):176-80. PubMed ID: 23091108
    [No Abstract]   [Full Text] [Related]  

  • 24. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
    Nagar S; Blanchard RL
    Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenomics of endocrine therapy in breast cancer.
    Weinshilboum R
    Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should CYP2D6 be genotyped when treating with tamoxifen?
    Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
    Pharmacogenomics; 2017 Jun; 18(8):755-756. PubMed ID: 28593824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
    Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
    J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
    Deeken JF; Slack R; Marshall JL
    Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
    Province MA; Goetz MP; Brauch H; Flockhart DA; Hebert JM; Whaley R; Suman VJ; Schroth W; Winter S; Zembutsu H; Mushiroda T; Newman WG; Lee MT; Ambrosone CB; Beckmann MW; Choi JY; Dieudonné AS; Fasching PA; Ferraldeschi R; Gong L; Haschke-Becher E; Howell A; Jordan LB; Hamann U; Kiyotani K; Krippl P; Lambrechts D; Latif A; Langsenlehner U; Lorizio W; Neven P; Nguyen AT; Park BW; Purdie CA; Quinlan P; Renner W; Schmidt M; Schwab M; Shin JG; Stingl JC; Wegman P; Wingren S; Wu AH; Ziv E; Zirpoli G; Thompson AM; Jordan VC; Nakamura Y; Altman RB; Ames MM; Weinshilboum RM; Eichelbaum M; Ingle JN; Klein TE;
    Clin Pharmacol Ther; 2014 Feb; 95(2):216-27. PubMed ID: 24060820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
    Fujita K; Kubota Y; Ishida H; Sasaki Y
    World J Gastroenterol; 2015 Nov; 21(43):12234-48. PubMed ID: 26604633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
    Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
    Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.
    Brauch H; Schwab M
    Br J Clin Pharmacol; 2014 Apr; 77(4):695-703. PubMed ID: 24033728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding CYP2D6 and its role in tamoxifen metabolism.
    Smith EC
    Oncol Nurs Forum; 2013 Nov; 40(6):547-8. PubMed ID: 24161632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.
    Damkier P
    Pharmacogenomics; 2017 Jun; 18(8):753-754. PubMed ID: 28592184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
    Rouits E; Boisdron-Celle M; Dumont A; Guérin O; Morel A; Gamelin E
    Clin Cancer Res; 2004 Aug; 10(15):5151-9. PubMed ID: 15297419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
    Kiyotani K; Mushiroda T; Zembutsu H; Nakamura Y
    J Hum Genet; 2013 Jun; 58(6):327-33. PubMed ID: 23657426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
    Stearns V; Rae JM
    Expert Rev Mol Med; 2008 Nov; 10():e34. PubMed ID: 19019258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.